Andy is our CEO and Founder. Following his MSc., Andy’s first foray into biotech was as a bench scientist supporting the release of a live, attenuated influenza vaccine. He got a taste of the dynamic world that is the ‘CRO’, and this has been his passion for the past 15 years. In 2007, Andy moved to Scotland and launched a new CRO, BioOutsource Ltd.
In 2015, Andy founded RoukenBio and has spearheaded its rapid growth. In a short period of time, Andy has transformed it from a niche CRO to being the trusted outsourced research partner for global novel drug developers and biosimilar developers alike. Andy’s vision is for RoukenBio to be the research provider of choice, supporting developers from the very earliest phases of drug discovery and through the clinic.
“I am passionate about growing a sustainable organisation that pushes the boundaries of what it means to be a CRO. My goal is to deliver innovation in all aspects of the business, by responding to the challenges faced by innovative drug developers with new approaches and by mentoring staff to reach their full potential. All the while, my aim is for our teams to provide the highest quality service and data to our customers.” - Andy Upsall
Resources
Insights
28 October 2024
|6 min read
Read the first installment of our Building your Bioassay blog series with Quantics Biostatistics!
Whitepapers
18 October 2022
|5 min read
Successful approval of biological medicinal products in the EU and US requires characterisation of the biological product’s properties to enable the setting of specifications that control the molecule’s critical quality attributes (CQA) for release into the clinic and onto the market. Release specifications ensure manufacturing lot-to-lot consistency, product stability, and ultimately, patient safety. So, what are the main development considerations? We delve into these to future-proof your potency assays.
